https://www.selleckchem.com/pr....oducts/cucurbitacin-
4 ± 0.7 to 0.6 ± 0.7 (p 0.001) at 3months. Maximum flow rate increase by 44% from 9.26 ± 2.5 to 13.34 ± 2.3mL/s (p 0.001). When compared to ten matched patients undergoing TURP in the same period, there was a significant cost saving of €1986.52 per patient for Rezum, overall up-front cost saving of €22,819 with an additional 19 bed days and 5 theatre hours spared. Rezum, a minimally invasive thermal therapy, provides significantly improved symptom relief and quality of life with a significant cost saving to the institut
Like
Comment
Share
